New hires and promotions in the biopharma industry, including: Akari, Fairjourney, Crinetics, Fibrogen, Kalvista, Neophore, Neural, Vectory, Xilio.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: ARS, Ascendis, Bridgebio, Eli Lilly, Galderma, Geron, Gilead, Merck, Roche, Sanofi.

The top 10 biopharma stock gainers and losers for the week.

A quick look back at top stories.

Total raised in public, private and other financings of biopharma companies, comparing 2019-2024.

Year-to-date money raised in public, private and other financings of biopharma companies.

GC Biopharma Corp. will buy plasma collector Abo Holdings Inc. in a ₩138 billion (US$96.28 million) cash acquisition as the vaccine and plasma-derived medicinal products developer works to accelerate entry of Alyglo (IVIG-SN 10%) in the U.S., where it was approved last year.

The EMA’s Committee for Medicinal Products for Human Use recommended 17 drugs for approval at its December meeting, bringing the total for 2024 to 114. That is up from the 77 drugs recommended for approval in 2023, of which 39 were novel.

Mixed results for three of Bicycle Therapeutics plc’s zelenectide pevedotin development programs preceded a strong drop in the company’s stock. Bicycle shares (NASDAQ:BCYC) dropped 31.3% on Dec. 13 to close at $13.81 each, the stock’s lowest price in the past 12 months.